AVXL (Anavex Life Sciences) Tax Provision: $-0.02 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVXL Anavex Life Sciences Corp AVXL
26 GF Score
Price $2.43
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences Tax Provision?

Anavex Life Sciences AVXL -0.82% 26 Tax Provision is $-0.02 Mil as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Anavex Life Sciences's tax provision for the three months ended in Dec. 2025 was $-0.02 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02 Mil.

Anavex Life Sciences Tax Provision Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences Tax Provision Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 -0.36 -0.01 0.00 0.00

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.02
AVXL
26GF Score
Anavex Life Sciences Corp AVXL
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-0.02 Mil mean?
Anavex Life Sciences (AVXL) has a Tax Provision of $-0.02 Mil as of Dec. 2025. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Anavex Life Sciences and its competitors.
Is Anavex Life Sciences' Tax Provision too high?
Anavex Life Sciences' current Tax Provision is $-0.02 Mil. Overall, Anavex Life Sciences has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Tax Provision compare to SLGL and FATE?
Anavex Life Sciences' Tax Provision of $-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current Tax Provision is $-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Tax Provision of $-0.02 Mil. The current Tax Provision is $-0.02 Mil. Anavex Life Sciences' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Tax Provision is $-0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
26GF Score

Get the complete analysis for AVXL

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.43
Price